Compare Enveric Biosciences Inc (ENVB) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs KKR & Co Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while KKR & Co Inc trades at $90 (market cap $80.39B). The key difference: KKR & Co Inc is far larger — about 11822.1× Enveric Biosciences Inc's market cap, and KKR & Co Inc pays a 0.87% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and KKR & Co Inc for 67 Days on average.
| ENVB | KKR | |
|---|---|---|
Market Cap | $6.80M | $80.39B |
Volume | 64,867 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $10.80 | $142.75 |
52-Week Low | $1.27 | $83.88 |
Typical Hold Time | 14 Days | 67 Days |
Enterprise Value | -$1.49M | $2.95B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
KKR trades at $89.67, down 1.1% on the day, with a bearish technical signal but strong analyst support. Recent earnings show beats in Q1 and Q2 2026, with revenue of $19.21B in 2025 and net income of $2.37B. The stock is supported by a consensus price target of $123.30, indicating significant upside potential. News highlights active deal-making, including joint ventures and asset sales, reinforcing its global investment firm strategy.
The outlook for KKR is positive based on robust fundamentals and analyst optimism, though technical indicators suggest near-term caution. Investment opportunities include potential price appreciation toward the consensus target and ongoing strategic investments. Risks involve market volatility, execution of large-scale deals, and macroeconomic factors affecting asset management returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
